Everolimus in the Treatment of Metastatic Breast Cancer

Everolimus in the Treatment of Metastatic Breast Cancer

Show other versions (1)

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including horm...

Full description

Bibliographic Details
Main Authors: Melanie E. Royce, Diaa Osman
Format: Article
Language:English
Published: SAGE Publishing 2015-01-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.4137/BCBCR.S29268
id doaj-cdef68d60a0c4fcfa698f3e5628803bb
record_format Article
spelling doaj-cdef68d60a0c4fcfa698f3e5628803bb2020-11-25T02:34:07ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342015-01-01910.4137/BCBCR.S29268Everolimus in the Treatment of Metastatic Breast CancerMelanie E. Royce0Diaa Osman1Multidisciplinary Breast Cancer Clinic and Program, University of New Mexico Cancer Center, Albuquerque, NM, USA.Multidisciplinary Breast Cancer Clinic and Program, University of New Mexico Cancer Center, Albuquerque, NM, USA.The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor–positive, human epidermal growth factor receptor–negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.https://doi.org/10.4137/BCBCR.S29268
collection DOAJ
language English
format Article
sources DOAJ
author Melanie E. Royce
Diaa Osman
spellingShingle Melanie E. Royce
Diaa Osman
Everolimus in the Treatment of Metastatic Breast Cancer
Breast Cancer: Basic and Clinical Research
author_facet Melanie E. Royce
Diaa Osman
author_sort Melanie E. Royce
title Everolimus in the Treatment of Metastatic Breast Cancer
title_short Everolimus in the Treatment of Metastatic Breast Cancer
title_full Everolimus in the Treatment of Metastatic Breast Cancer
title_fullStr Everolimus in the Treatment of Metastatic Breast Cancer
title_full_unstemmed Everolimus in the Treatment of Metastatic Breast Cancer
title_sort everolimus in the treatment of metastatic breast cancer
publisher SAGE Publishing
series Breast Cancer: Basic and Clinical Research
issn 1178-2234
publishDate 2015-01-01
description The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor–positive, human epidermal growth factor receptor–negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.
url https://doi.org/10.4137/BCBCR.S29268
work_keys_str_mv AT melanieeroyce everolimusinthetreatmentofmetastaticbreastcancer
AT diaaosman everolimusinthetreatmentofmetastaticbreastcancer
_version_ 1724810051010428928

Similar Items